Cerep Inks Kinase-Profiling Agreement with Lilly | GenomeWeb

NEW YORK (GenomeWeb News) - Cerep today said that it has signed an agreement with Eli Lilly & Co. covering the use of its kinase assay platform to study undisclosed drug targets.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Cerep's kinase profiling service is based on PerkinElmer's Lance Ultra kinase assay technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.